Jupiter Topco LLC Invests $2.93 Million in West Pharmaceutical Services, Inc. $WST

Key Points

• Jupiter Topco LLC purchased 8,172 West Pharmaceutical Services shares worth approximately $2.93 million during the second quarter. Institutional investors and hedge funds collectively own 93.9% of WST’s outstanding shares.
• Wall Street analysts maintain a generally bullish view, with a consensus rating of “Moderate Buy” and an average price target of $368.08; recent targets ranged from $360 to $447.
• West Pharmaceutical Services exceeded quarterly earnings expectations, reporting $2.37 in EPS and $872.3 million in revenue, up 13.8% year over year. The company also paid a quarterly dividend of $0.22, equivalent to a 0.3% annualized yield.

Jupiter Topco LLC bought a new position in shares of West Pharmaceutical Services, Inc. (NYSE:WST - Free Report) during the second quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor bought 8,172 shares of the medical instruments supplier's stock, valued at approximately $2,934,000.

Several other hedge funds have also recently added to or reduced their stakes in the company. Addison Advisors LLC purchased a new position in West Pharmaceutical Services in the second quarter worth approximately $28,000. Avalon Trust Co purchased a new stake in shares of West Pharmaceutical Services in the 2nd quarter valued at approximately $28,000. Elyxium Wealth LLC purchased a new stake in shares of West Pharmaceutical Services in the 4th quarter valued at approximately $25,000. Bayban acquired a new stake in shares of West Pharmaceutical Services in the 4th quarter valued at $27,000. Finally, DV Equities LLC purchased a new stake in shares of West Pharmaceutical Services during the 4th quarter worth $28,000. Institutional investors and hedge funds own 93.90% of the company's stock.

Wall Street Analysts Forecast Growth

Several research firms recently commented on WST. Evercore reissued an "outperform" rating and issued a $425.00 target price on shares of West Pharmaceutical Services in a report on Monday, July 27th. Stephens reaffirmed an "overweight" rating and set a $360.00 price target on shares of West Pharmaceutical Services in a report on Tuesday, June 2nd. Morgan Stanley upped their price objective on West Pharmaceutical Services from $325.00 to $365.00 and gave the stock an "equal weight" rating in a research report on Thursday, July 9th. Weiss Ratings upgraded West Pharmaceutical Services from a "hold (c)" rating to a "hold (c+)" rating in a report on Friday, August 7th. Finally, BNP Paribas Exane began coverage on West Pharmaceutical Services in a research report on Monday, July 13th. They set an "outperform" rating and a $447.00 target price on the stock. One equities research analyst has rated the stock with a Strong Buy rating, eleven have assigned a Buy rating and three have assigned a Hold rating to the company's stock. According to data from MarketBeat.com, West Pharmaceutical Services has an average rating of "Moderate Buy" and a consensus target price of $368.08.

West Pharmaceutical Services Stock Up 1.2%

WST opened at $342.88 on Thursday. The business's 50-day simple moving average is $350.87 and its 200-day simple moving average is $306.04. The company has a debt-to-equity ratio of 0.07, a quick ratio of 2.12 and a current ratio of 2.82. West Pharmaceutical Services, Inc. has a one year low of $223.83 and a one year high of $386.00. The stock has a market capitalization of $24.13 billion, a P/E ratio of 43.90, a price-to-earnings-growth ratio of 2.37 and a beta of 1.14.

West Pharmaceutical Services (NYSE:WST - Get Free Report) last announced its earnings results on Thursday, July 23rd. The medical instruments supplier reported $2.37 earnings per share (EPS) for the quarter, beating analysts' consensus estimates of $2.08 by $0.29. The firm had revenue of $872.30 million during the quarter, compared to analysts' expectations of $839.98 million. West Pharmaceutical Services had a return on equity of 20.11% and a net margin of 16.98%.The business's revenue was up 13.8% on a year-over-year basis. During the same period in the prior year, the firm earned $1.84 EPS. West Pharmaceutical Services has set its Q3 2026 guidance at 2.140-2.240 EPS and its FY 2026 guidance at 8.850-9.050 EPS. Analysts anticipate that West Pharmaceutical Services, Inc. will post 8.93 EPS for the current year.

West Pharmaceutical Services Announces Dividend

The company also recently disclosed a quarterly dividend, which was paid on Wednesday, August 5th. Stockholders of record on Wednesday, July 29th were issued a $0.22 dividend. This represents a $0.88 annualized dividend and a dividend yield of 0.3%. The ex-dividend date of this dividend was Wednesday, July 29th. West Pharmaceutical Services's dividend payout ratio is presently 11.27%.

West Pharmaceutical Services Profile

West Pharmaceutical Services, Inc is a global developer and manufacturer of components, systems and services that enable the containment and delivery of injectable drugs. The company focuses on high-quality packaging and delivery solutions for the pharmaceutical and biotech industries, producing primary drug packaging components and specialized drug delivery devices used for vaccines, biologics and other injectable therapies. West is known for its elastomeric closures, seals and polymer components that maintain sterility and compatibility with sensitive drug formulations.

In addition to component manufacturing, West provides engineered delivery systems and support services across the product lifecycle.

Want to see what other hedge funds are holding WST? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for West Pharmaceutical Services, Inc. (NYSE:WST - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Continue following MarketBeat

Add MarketBeat as your preferred source on Google to see our latest stories in your feed.

Add As Preferred Source